Gastric Neuroendocrine Carcinoma
NCI Definition: An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the stomach. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma. 
Gastric neuroendocrine carcinomas most frequently harbor alterations in TP53, RB1, ATM, VHL, and TSHR .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Mutation, and ATM Mutation are the most common alterations in gastric neuroendocrine carcinoma .
There is 1 clinical trial for gastric neuroendocrine carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains gastric neuroendocrine carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in gastric neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.